Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab-rwlc (Libtayo) in Subjects With Recurrent or Progressive Glioblastoma

Trial Profile

A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab-rwlc (Libtayo) in Subjects With Recurrent or Progressive Glioblastoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary) ; INXN 2001 (Primary) ; Veledimex (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ZIOPHARM Oncology
  • Most Recent Events

    • 07 Nov 2019 According to a ZIOPHARM Oncology media release, the first first six patients have been dosed in this study and are completing the required monitoring period prior to the resumption of enrollment.
    • 01 Jul 2019 Status changed from planning to recruiting.
    • 27 Jun 2019 According to a ZIOPHARM Oncology media release, this trial will be conducted at approximately 10 hospitals specializing in the treatment of brain cancers in the United States.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top